5 Best Weight Loss Drug Stocks to Buy Now

3. Amgen Inc. (NASDAQ:AMGN)

Number of Q4 2023 Hedge Fund Shareholders: 69

Amgen Inc. (NASDAQ:AMGN) is an American healthcare company headquartered in Thousand Oaks, California. It is developing an injectable weight loss drug called MariTide as an alternative to popular treatments from Novo Nordisk. The shares are rated Buy on average, and the average share price target is $308.50.

For their fourth quarter of 2023 shareholdings, 69 out of the 933 hedge funds profiled by Insider Monkey had bought Amgen Inc. (NASDAQ:AMGN)’s shares. Josh Overdeck and David Siegel’s Two Sigma Advisors owned the biggest stake which was worth $333 million.

Follow Amgen Inc (NASDAQ:AMGN)